Periodontal disease drug pipeline analysis and market forecasts to 2016
Download
1 / 4

Periodontal Disease Drug Pipeline Analysis to 2016 - PowerPoint PPT Presentation


  • 568 Views
  • Uploaded on

The Periodontal Disease Market is Estimated to Grow at a Compound Annual Growth Rate (CAGR) of 6.4% from 2009 to 2016

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Periodontal Disease Drug Pipeline Analysis to 2016' - rgunnam


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Slide2 l.jpg

The Periodontal Disease Market is Estimated to Grow at a Compound Annual Growth Rate (CAGR) of 6.4% from 2009 to 2016

The global periodontal disease market was valued at $1,248m in 2009 and is forecast to grow by 6.4% annually for the next seven years to reach $1,937m in 2016. The periodontal disease market is characterized by efficacious dental procedures such as scaling, root planing and surgery. The periodontal therapeutics market comprises Local Applied Antibody (LAA) and systemic applied antibody. The sales of Periochip, Arestin, Atridox, Periostat and Doxycyline (generics) contribute to the periodontal therapeutics market size. The influx of new drugs and the increase in uptake of the LAA will the drive the market in the forecast period.

The LAA and Systemic Application of the Antibiotics are Adjuvant Therapies to the Main Stream Dental Procedures

The market comprises drugs such as Periochip, Arestin, Atridox, Periostat and generics like doxycyline and minocycline. All of these drugs are employed as the adjuvant therapy to scaling, root planing and flap surgery. Periodchip, Arestin, Atridox are LAAs that are applied to the gum pockets after the scaling and root planing. These LAAs are employed as adjuvant therapies that help the gums pockets heal more quickly. The LAA therapy is more expensive than the systemic administration of the antibiotics. However, increased efficacy coupled with patient convenience will drive the market in the forecast period.

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Periodontal-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

Weak Pipeline Consists of Only Five Molecules in Phase III

There are 19 molecules in the various phases of the developmental pipeline. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. Combinations of the various tetracylines are expected to improve the efficacy of the treatment. The pipeline candidates are similar in nature to the marketed drugs.


Slide3 l.jpg

Current Treatment Options Satisfactorily Serve the Market Needs and are Curative

Scaling, root planing and surgery are the chief treatment therapies employed by dentists to treat periodontal disease. The therapeutics drugs Periochip, Arestin, Atridox, Periostat and Doxycyline are adjuvant to dental procedures like scaling, root planing and surgery. After the process of scaling and root planing either LAA or systemic antibiotic therapy is employed to maintain the hygiene of the gum pockets. In the case of scaling or root planing the LAA is inserted in the gum pockets. The LAAs are a slow release formulation of the antibiotic Minocycline. It is formulated to deliver the antibiotic for 11 days. The measured release of antibiotic remains effective for 12 to 13 weeks. After surgery the patient is often treated with doxycyline for 5 to ten days. In summation, the market is well served with the current treatment options.

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Periodontal-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

GlobalData has released its research “Periodontal Disease - Drug Pipeline Analysis and Market Forecasts to 2016”. The report provides key data, information and analysis on the global periodontal disease market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts for seven years to 2016. The report provides coverage of the market landscape, market drivers and restraints, and an in-depth pipeline analysis. The current competitive landscape is also analyzed and the unmet need and commercial opportunity of the market is calculated. The pipeline analysis covers molecules across all phases of clinical development and provides an overview of the developing trends among the pipeline molecules, as well as an insight into the most promising pipeline drugs supplemented with key company profiles. By considering the current competition in the market and the prospects of the pipeline molecules, the resulting implications for the future market competition are also outlined.


Slide4 l.jpg

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Periodontal-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

Or visit our report store: http://www.globaldata.com/reportstore

Contact Information:

Rajesh Gunnam

[email protected]

+914066166782


ad